ERBB3 and thyroid cancer: In thyroid cancer cells, resistance to BRAFV600E inhibitors is largely due to activation of HER3 signaling, as supported by the effect of HER kinase inhibitor lapatinib which prevents MAPK signaling recovery, and sensitizes thyroid cancer cells to RAF inhibitors [12].